Conference Day Two | Thursday, October 17
8:00 am Morning Networking Coffee
8:50 am Chair’s Opening Remarks
Overcoming TGF-β Therapeutic Toxicity by Design, Dosage & Delivery to Achieve Better Clinical Results
9:00 am Defeating the Highly Potent Toxicity of ADCs Targeting TGF-β for Effective Patient Response
Synopsis
- Evolving the ALK5 inhibitor payload to achieve patient treatment success
- Targeting TGF-β receptors using ADC to avoid toxicity in the heart and bone
- Avoiding systematic toxicity in TGF-β directed therapies by highly specific targeting for better patient response
9:30 am Reimagining Precision Delivery to Enable TGF-β Therapies at Ultra-Low, Nontoxic Doses
Synopsis
- Proving how endothelium is the critical barrier to low dose precision therapeutic efficacy without toxicities
- New dual precision therapeutics to penetrate endothelium and to fully block TGF-β only inside the lung
- Transvascular pumping of drugs by design boosts site delivery and potency 1000x and circumnavigates toxicity
New Data!
10:00 am Selectively Targeted TGF-β Activating Integrin, αvβ8 & αvβ8 in Solid Tumors to Increase Sensitivity to Checkpoint Inhibition Therapies
Synopsis
- Avoiding systemic toxicity by selective tatrgeting of TGF-β activating integrins in the tumor microenvironment with an oral small molecule inhibitor
- Anti-tumor activity from blocking distinct integrin-regulated TGF-β pathways on T-cells, tumor and stromal cells
- Activity as both a single agent in combination with checkpoint inhibitors in multiple animal models
10:30 am Morning Networking Break & Poster Session
Synopsis
Contribute to the conversation and share your cutting-edge research with your fellow TGF-β community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster*
*Please visit the website for the T&Cs for presenting a poster
Employing Improved Animal Models in the Development of TGF-β Directed Therapies for Better Translation
11:00 am Overcoming Problems with Animal Models by Exploring GEM-Derived Allograft Models to Improve Translational Success
Synopsis
- Exploring models to mimic tumor stroma in animal models to have a more accurate picture of human tumors
- Developing genetically engineered model (GEM)-derived allografts to recapitulate stromal contexture of solid tumors
- Modeling cold solid tumors in mice for preclinical evaluation of immunotherapy combinations
11:30 am Employing Small Molecule Design as a Safeguard Against Toxicity of TGF-β Targeted Therapies
Synopsis
- Targeting TGF-β activation to reduce unwanted side effects
- Making treatments directed to TGF-β safe and efficacious by stimulating T cell responses and reducing fibrosis
- Exploring response of αvβ8 inhibitor in mouse tumor models
12:00 pm Networking Lunch
Investigating Approaches to Improve Translation from Animals to the Clinic for TGF-β Directed Therapies
1:00 pm Selective Targeting GARP–TGF-β1 Increases Antitumor Activity by Remodeling the Immunosuppressive Tumor Microenvironment
Synopsis
- Developing superior translational models for more accurate representation of patient tumors
- Elucidating the mechanism-of-action by analyzing the tumor microenvironment pre- and post-treatment
- Exploring biomarkers associated with improved results in the combination setting with anti-PD1
1:30 pm Roundtable Discussion: Boosting Clinical Efficacy by Using Alternative & Novel Models for Better Transition to the Clinic
Synopsis
- Harnessing innovative models to improve translation from animals to humans
- Exploring organoid alternatives to animals that can show more accurate response to TGF-β targeted therapies
- Pioneering novel human cell models to follow a patients’ response to all therapies for better understanding of effective TGF-β targeted therapies
2:00 pm Afternoon Networking Break
Unlocking Alternative Modalities to Direct TGF-β Therapies with Low Immunogenicity & Better Therapeutic Effiacy
2:30 pm Developing a Novel Small Molecule Oxysterol as a Potent Inhibitor of TGF-β
Synopsis
- Utilizing Oxy210 as a poly-pharmacological drug candidate to target 3 main signaling pathways in fibroblasts and other cells involved in fibrosis and inflammation
- Demonstrating the intact TGF-β-mediated immune cell responses upon Oxy210 treatment
- Evaluating the therapeutic effects of Oxy210 on chronic inflammatory diseases associated with metabolic dysfunction
New Data!
3:00 pm Using Oncolytic Viruses to Target TGF-β in the Tumor Microenvironment
Synopsis
- Directly targeting tumors using OVs to avoid systematic toxicity for better patient response
- Targeting the TGF-β receptors with oncolytic viruses for strong immune response
- Uncovering preclinical success using OVs to show clinical efficacy
New Data!
3:30 pm Innovative Strategies in TGF-β Therapy: Selective Targeting, Synergistic Combinations, and Cutting-Edge Modalities
Synopsis
- Demonstrating the use of bispecific antibodies and small molecule inhibitors to selectively block TGF-β oriented targets, reducing off-target effects and improving therapeutic outcomes
- Spotlighting the synergy between TGF-β inhibitors and immune checkpoint inhibitors in combination therapies to boost anti-tumor immunity, reduce systemic toxicity, and achieve superior clinical results in cancer and non-cancer therapy
- Highlighting the integration of TGF-β therapies with innovative modalities including RNAbased therapies and TGF-β armored cell therapies to enhance therapeutic precision, efficacy, and specificity